StockWatch
·
Medicinal Chemicals & Botanical Products
Quarterly ResultAug 6, 2026, 07:51 AM

Cresco Labs Q2 Revenue $173M, Net Income $15M, Adj. EBITDA $40M

AI Summary

Cresco Labs Inc. reported strong financial results for the second quarter ended June 30, 2026, with revenue increasing to $173 million and a significant turnaround to a net income of $15 million from a prior-year loss. The company also achieved an Adjusted EBITDA of $40 million and maintained its No. 1 market share position in several key markets. Additionally, Cresco Labs secured a new $50.0 million Revolving Credit Facility during the quarter.

Key Highlights

  • Second quarter 2026 revenue was $173 million, up from $163.6 million in Q2 2025.
  • Net income for Q2 2026 was $15 million, a significant improvement from a net loss of $13.9 million in Q2 2025.
  • Adjusted EBITDA for Q2 2026 reached $40 million, with an Adjusted EBITDA margin of 22.8%.
  • Basic income per share was $0.05 for Q2 2026, compared to a loss of $0.05 in Q2 2025.
  • Gross profit for Q2 2026 was $87 million, with an Adjusted gross margin of 51.6%.
  • SG&A was $63 million (36.5% of revenue), with Adjusted SG&A at $55 million (32.0%).
  • The company secured a $50.0 million Revolving Credit Facility on June 5, 2026.